Phase 1 data indicate invikafusp alfa's potential as a precision cancer immunotherapeutic in solid tumors that have ...

The biotherapeutics company said the treatment, LYT-200, is being evaluated in two ongoing clinical trials. It was previously granted orphan drug designation for the treatment of acute myeloid ...

(Alliance News) - PureTech Health PLC on Thursday said that the US Food & Drug Administration has granted fast track designation to its antibody LYT-200 for the treatment of acute myeloid leukemia.

LYT-200 is currently being evaluated in two Phase 1/2 trials for the potential treatment of AML/MDS and head and neck cancers PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company” ...

Repurposed Drug use for cancer is exploding around the world. And today, New Year’s Day 2025, even Artificial Intelligence is ...

An Institute for Value-Based Medicine regional event in Houston, Texas, covered inconsistencies with the integration of precision medicine in oncology practices, the evolution of treatment for ...

GORTEC, known as Head and Neck Radiation Oncology Group, today announced that the randomized Phase 3 NIVOPOSTOP GORTEC ...

PF-07921585 is under clinical development by Pfizer and currently in Phase I for Metastatic Colorectal Cancer.

CX-801 is under clinical development by CytomX Therapeutics and currently in Phase I for Metastatic Melanoma. According to GlobalData, Phase I drugs for Metastatic Melanoma have an 81% phase ...

While tobacco and alcohol are known to increase the risk of head and neck cancer, new research has found the amount of coffee ...

The Jimmy Carter drug introduced the world to cancer immunotherapy, a treatment that differs from chemotherapy. Carter was ...